Primary sclerosing cholangitis in Turkish patients:characteristic features and prognosis

来源 :国际肝胆胰疾病杂志:英文版 | 被引量 : 0次 | 上传用户:liongliong520
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
BACKGROUND:Primary sclerosing cholangitis(PSC)is a chronic cholestatic liver disease characterized by destruction and fibrosis of the bile ducts.This study aimed to demonstrate the hepatic and extrahepatic characteristic findings and prognostic outcomes o
其他文献
BACKGROUND:Dendritic cells(DCs)are the most important antigen-presenting cells in the human body,and DCs with different mature status possess different or even
BACKGROUND:Cystic dystrophy in heterotopic pancreas (CDHP)is a rare benign condition characterized by the presence of cysts in the wall of the digestive tract a
BACKGROUND:Primary myelofibrosis(PMF)is a myelopro-liferative disorder characterized by bone marrow fibrosis. Extra-medullary hematopoiesis sometimes occurs eve
BACKGROUND:Mechanical lithotripsy and/or stent insertion is the alternative therapeutic approach in difficult endoscopic retrograde cholangiopancreatography (ER
BACKGROUND:Spinal tuberculosis is a common disease in orthopedic clinical practice;however,it is seldom reported after organ transplantation.The aim of this stu
【正】To the Editor: Dietary supplements and herbal products are an increasingly common source of drug-induced liver injury. An increasing number of case report
期刊
In live donor liver transplantation,anatomical anomalies of the portal vein are more frequently encountered in right lobe than left lobe grafts.Of these,a dual
BACKGROUND:Hepatocellular carcinoma(HCC)is one of the most common malignant tumors.We analyzed the expression of nuclear-transcription factor-kappa B(NF-κB) du
BACKGROUND:Although hepatic resection is widely accepted as a proper modality for treating hepatocellular carcinoma(HCC),a majority of patients are unable to un
BACKGROUND: This study was designed to probe the clinical value in assessing the degree of liver cirrhosis by using the arrival time of contrast agent in the ri